Clinical-stage biotech targeting Multiple Sclerosis & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS™️. Diversified Treasury. NASDAQ: $QNTM
Joined June 2018
- Tweets 1,254
- Following 384
- Followers 5,982
- Likes 696
765 Photos and videos
Jun 8
Multiple sclerosis remains a major unmet medical challenge.
Quantum BioPharma's investigational drug candidate, Lucid-MS, is a new chemical entity (NCE) being developed to target citrullination-driven demyelination through a non-immunosuppressive and non-immunomodulatory approach.
Research suggests excessive citrullination may alter myelin proteins and contribute to myelin damage, impacting nerve signaling.
✅ Novel mechanism under investigation
✅ Focused on demyelination biology
✅ Addressing an important unmet need in MS research
Lucid-MS is investigational and not approved by the FDA or Health Canada.
$QNTM #MultipleSclerosis #MSResearch #Biotech #Neuroscience #DrugDevelopment #ClinicalTrials #HealthcareInnovation
quantumbiopharma.com
3
10
955
Jun 5
Quantum BioPharma continues advancing its Lucid-MS program with a focus on demyelination and neuroprotective pathways in Multiple Sclerosis.
Phase 1 complete. IND submitted for Phase 2 trial design.
Lucid-MS is investigational and not approved by FDA or Health Canada.
Sign up for email alerts : quantumbiopharma.com/email-a…
#Biotech #MultipleSclerosis #Demyelination $QNTM
1
10
896
Jun 2
Quantum BioPharma $QNTM is featured on The BioMedWire Podcast.
Anthony Durkacz (@AnthonyDurkacz ) discusses Lucid-MS, multiple sclerosis research, unbuzzd™, and key 2026 milestones.
Watch the full episode:
youtube.com/watch?v=clA0PZNf…
#QNTM #QuantumBioPharma #LucidMS #BiotechStocks #MultipleSclerosis
1
964
245
2,084
Jun 1
Jun 1
A 180-page commercialization study by Eversana projects $160 million in conservative first-year sales for Lucid-MS.
The report surveyed patients, doctors, key opinion leaders, and insurers across North America, Europe, and Japan.
Issued on behalf of @QuantumBP $QNTM
- MS market projected to exceed $30 billion by 2030
- Eversana validated demand from patients, physicians and insurers globally
Watch the full interview on AGORACOM Hub.
1
6
515
Jun 1
May 5
On May 31, at #MSWalk, we’ll come together to show what happens when people show up for one another and for the future we all want to see, and we want you to join us.
Walk for your loved ones. Walk for your community. Walk for the cause. Register today: bit.ly/4waRQbt
1
4
236
Jun 1
A big shout out to everyone who participated and supported this years #MSWalk!!
Every step fuels awareness, support, and research for those affected by MS!
@MSCanOfficial
1
3
158
Jun 1
Jun 1
Quantum BioPharma submitted its Phase 2 IND to the FDA on March 30. Management said FDA clearance could come within 45 to 60 days.
Issued on behalf of @QuantumBP $QNTM
The 90-day toxicology study is now complete and submitted. Remaining FDA questions relate to interactions with existing MS therapies.
- FDA has a 30-day window to respond; management expects a letter imminently
- Internal team and CRO estimate 10 to 15 days to address any deficiencies
- If FDA raises no further concerns after responses are submitted, clearance follows
Watch the full interview on AGORACOM Hub.
1
5
416
Jun 1
Most approved MS therapies are designed to modulate or suppress the immune system.
But the immune system may not be the whole story.
For decades, MS treatment has largely focused on reducing immune-driven attacks. Quantum BioPharma $QNTM is exploring a different scientific question: whether MS also involves neurodegenerative mechanisms tied directly to myelin damage.
This is the demyelination pathway.
Lucid-MS, also known as LUCID-21-302, is being developed as a non-immunomodulatory investigational new chemical entity designed to target PAD2 an enzyme involved in abnormal myelin protein citrullination, a process believed to increase myelin vulnerability in MS.
In preclinical animal models, Lucid-MS demonstrated signals supporting further research into this mechanism.
Rather than targeting the immune system, Lucid-MS is focused on the biology of demyelination itself.
A different mechanism. A different pathway. A different approach to MS research. No Drugs currently on the market that are approved do what Lucid-MS is designed to do.
Lucid-MS is a Investigational drug candidate. Not approved by the FDA or Health Canada. Currently in clinical development.
#Multiplesclerosis
2
9
1,458
Jun 1
May 31
MS Walk Day is here! 🎉
Across the country, thousands of people are coming together to raise awareness for Canadians living with #MS and their families.
Every participant, volunteer, and supporter brings us closer to a world free of MS ❤️.
#MSWalk #MultipleSclerosis
1
3
157
May 26
Quantum BioPharma recently announced a key midpoint milestone in its separate collaborative imaging study with Massachusetts General Hospital, centered on [¹⁸F]3F4AP PET imaging to help assess demyelination in Multiple Sclerosis.
While this study is separate from Lucid-MS trials, we believe this type of imaging research could one day help support the broader scientific understanding of how demyelination is measured and tracked in MS research.
Lucid-MS has completed prior Phase 1 clinical development, and Quantum BioPharma has submitted an IND application to the FDA for a Phase 2 clinical trial.
As Quantum BioPharma’s lead investigational candidate, Lucid-MS was designed to target neurodegenerative pathways linked to the citrullination cascade, representing a differentiated scientific approach from traditional immunomodulatory therapies.
Learn more in our May 18, 2026 news release.
globenewswire.com/news-relea…
$QNTM #Biotech #NASDAQ #Multiplesclerosis
2
16
846
May 26
Quantum BioPharma is proud to support #MSWalk and help raise awareness for those living with Multiple Sclerosis.
#MultipleSclerosis #MSAwareness #MSCommunity #MSResearch #Biotech
May 25
“My favourite part of MS Walk is being surrounded by others who understand what it’s like to live with MS, that sense of connection is everything.” – Tina, diagnosed in 2019
Join #MSWalk on May 31 and help make sure no one faces MS alone: bit.ly/49R5M0D
1
1
7
310
May 25
Quantum BioPharma CEO Interview with Zeeshan Saeed & Co Chair Anthony Durkacz | May 25, 2026
youtube.com/watch?v=_yRkfKv7…
#Biotech #Nasdaq #Multiplesclerosis #Neurodegenerative #Disease #Brainhealth #Interview #CEO $QNTM
3
2
12
916
May 25
Most current MS therapies primarily focus on immune modulation.
Quantum BioPharma’s Lucid-21-302 is being developed to target a different mechanism involving citrullination-driven neurodegenerative processes associated with Multiple Sclerosis.
Track Quantum BioPharma’s progress as we advance our pipeline through clinical development.
Subscribe for official company announcements, regulatory filings, and investor updates:
quantumbiopharma.com/email-a…
$QNTM #Biotech #Nasdaq #Multiplesclerosis
1
6
12
556
May 18
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis
globenewswire.com/news-relea…
#MGH #Harvard #Biotech #MS #MultipleSclerosis #PETStudy #PETtracer #Demyelination #LucidMS $QNTM
1
7
23
1,562
May 12
Quantum BioPharma recognizes that Multiple Sclerosis involves more than inflammation alone.
Scientific research has explored whether citrullination of Myelin Basic Protein (MBP) may alter myelin structure, contribute to demyelination, impair neural signaling, and play a role in neurodegenerative progression.
A different mechanism. A differentiated approach.
The unmet need in addressing the neurodegenerative component of MS remains significant.
Please visit quantumbiopharma.com for more info.
#LucidMS #MultipleSclerosis #MSResearch #Neurodegeneration #Demyelination #Biotech #Pharma #Neuroscience $QNTM
1
7
17
1,526
May 8
May 7
Multiple sclerosis involves damage to myelin — the protective layer surrounding nerve fibers.
Lucid-MS is being developed to target mechanisms associated with demyelination in MS.
Issued on behalf of @QuantumBP $QNTM
• Phase 1 safety and tolerability evaluation completed
• IND submitted as part of the regulatory process toward a planned Phase 2 program
What would you want to see demonstrated in future clinical development?
1
3
11
658